glp-1 oral drugs Market Overview: Agonists and the Obesity Market | Blog A new oral GLP-1 medication

A review in Diabetes Technology & Therapeutics concluded that while some studies showed small benefits, results were inconsistent across trials

Available from: Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM

Whilst GLP-1 receptor agonists are not prescribed solely for cholesterol reduction, certain patient groups may experience additional lipid-related benefits when these medications are used for their licensed indications

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif J

FDA labeling includes a boxed warning regarding thyroid C-cell tumors based on rodent studies, though human relevance remains uncertain

But when its linked to GLP-1s, gastroparesis usually isnt permanent